Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 6fludarabine phosphate 5Whole-Body Irradiation 5Mycophenolic Acid 4Tacrolimus 3Rituximab 3Peripheral Blood Stem Cell Transplantation 3Cyclosporine 3Busulfan 3fludarabine 2apixaban 2Methotrexate 2Melphalan 2Lenalidomide 2Etoposide 2CT-P10 2Biopsy 2Azacitidine 2venetoclax 1thymoglobulin 1merphos 1ivosidenib 1ibrutinib 1edoxaban 1Vorinostat 1Vancomycin 1Thiotepa 1Teicoplanin 1TAK-243 1Surveys and Questionnaires 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
TAK-243 × Classical hematology × 30 days × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡